Table 2.

Baseline concentrations of plasma markers of inflammation in patients with T2D according to outcome during 8–12 years of follow-up

Baseline 
Plasma MarkerOutcomeP Valuea
Alive (n=267)ESRD (n=59)Deceased (n=84)Alive Compared with ESRDAlive Compared
with DeceasedESRD Compared with Deceased
ICAM-1 (ng/ml)171 (141, 197)184 (159, 233)181 (147, 229)1.001.001.00
VCAM-1 (ng/ml)438 (358, 542)519 (451, 652)481 (424, 572)0.331.001.00
PAI-1 (ng/ml)15.6 (11.0, 24.3)15.2 (9.0, 24.5)16.6 (11.8, 21.1)0.991.001.00
IL-6 (pg/ml)1.6 (1.0, 2.3)2.3 (1.7, 3.6)2.3 (1.3, 3.4)1.000.051.00
CRP (mg/L)3.0 (1.2, 6.5)4.8 (1.9, 7.8)4.2 (1.5, 7.7)1.001.001.00
Free TNFα (pg/ml)3.9 (2.8, 5.5)8.3 (5.2, 11.1)4.9 (3.3, 7.6)0.0021.000.83
Total TNFα (pg/ml)10.3 (7.1, 14.4)23.0 (17.5, 29.4)14.1 (9.3, 21.3)0.021.000.35
TNFR1 (pg/ml)1184 (1005, 1446)2424 (2137, 3704)1588 (1174, 2066)<10−120.01<10−5
TNFR2 (pg/ml)2273 (1898, 2708)4745 (3735, 7018)2969 (2225, 3841)<10−110.02<10−4
  • Data are median (25th, 75th percentiles).

  • a Adjusted for significant covariates in Table 1 (age, systolic BP, AER, eGFR, insulin treatment, and renoprotective treatment) and Bonferroni corrected for the number of markers and groups compared (n=3×9).